News
After years of preparation, Eli Lilly is on the brink of launching a ... including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...
1don MSN
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...
Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results